関連ニュース

Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of th

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah NASDAQ: NYXH used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path t

Nyxoah SA (NYXH) Analyst/Investor Day Transcript